Bisson GP, Bastos ML, Campbell JR, Bang D, Brust JCM, et al.
2020-08-08 • Lancet
2020-08-08 • Lancet
BACKGROUND HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and...
Toit K, Altraja A, Acosta CD, Viiklepp P, Kremer K, et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING Estonia has a high proportion of multidrug-resistant tuberculosis (MDR-TB). It is important to link molecular and epidemiological data to understand TB transmission patterns....
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J, et al.
2012-08-28 • PLOS Medicine
2012-08-28 • PLOS Medicine
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the ...
Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, et al.
2016-09-01 • European Respiratory Journal
2016-09-01 • European Respiratory Journal
Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing ...
